Tiopronin 50 mg | 99.87%
TargetMol
Tiopronin, a sulfhydryl acylated derivative of glycine, leads to a reduction in urinary cystine concentration and subsequently reduces cystine stone formation.
More Information Supplier PageTiopronin
Search Results
Vidarabine 100 mg | 100.00%
TargetMol
Vidarabine is a nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
More Information Supplier PageVidarabine
Vidarabine 200 mg | 100.00%
TargetMol
Vidarabine is a nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
More Information Supplier PageVidarabine
Rimonabant 100 mg | 98.00%
TargetMol
Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including […]
More Information Supplier PageRimonabant
Rimonabant 10 mg | 98.00%
TargetMol
Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including […]
More Information Supplier PageRimonabant
Rimonabant 25 mg | 98.00%
TargetMol
Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including […]
More Information Supplier PageRimonabant
Rimonabant 50 mg | 98.00%
TargetMol
Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including […]
More Information Supplier PageRimonabant
Pirenzepine dihydrochloride 100 mg | 99.62%
TargetMol
Pirenzepine dihydrochloride is a selective M1 muscarinic receptor antagonist, inhibiting gastric secretion.
More Information Supplier PagePirenzepine dihydrochloride
Lacidipine 25 mg | 99.85%
TargetMol
Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia. It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure.
More Information Supplier PageLacidipine
Lacidipine 50 mg | 99.85%
TargetMol
Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia. It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure.
More Information Supplier PageLacidipine